CoChat

The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1

Open access
Ciccone, Lidia, Shi, Chenghui, di Lorenzo, Davide, Van Baelen, Anne-Cécile, Tonali, Nicolo · 2020 · Molecules

The DOI matches its Crossref record; 254 of the 256 references it cites were found in a registry or an index.

Abstract

Alzheimer’s disease (AD) represents a progressive amyloidogenic disorder whose advancement is widely recognized to be connected to amyloid-β peptides and Tau aggregation. However, several other processes likely contribute to the development of AD and some of them might be related to protein-protein interactions. Amyloid aggregates usually contain not only single type of amyloid protein, but also other type of proteins and this phenomenon can be rationally explained by the process of protein cross-seeding and co-assembly. Amyloid cross-interaction is ubiquitous in amyloid fibril formation and so a better knowledge of the amyloid interactome could help to further understand the mechanisms of amyloid related diseases. In this review, we discuss about the cross-interactions of amyloid-β peptides, and in particular Aβ1-42, with other amyloids, which have been presented either as integrated part of Aβ neurotoxicity process (such as Tau) or conversely with a preventive role in AD pathogenesis by directly binding to Aβ (such as transthyretin, cystatin C and apolipoprotein A1). Particularly, we will focus on all the possible therapeutic strategies aiming to rescue the Aβ toxicity by taking inspiration from these protein-protein interactions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/molecules25102439

Cites

254 of 254 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 A cross-amyloid network between Aβ peptide and four amyloidogenic proteins. Proteins with intrinsic amyloidogenic potential are contoured by red lines. Green symbols: amyloid proteins that have a positive effect against the progression of AD. Red dashes arrow: amyloid protein pathway according to the amyloid cascade hypothesis. The details of the interactions are discussed in the review for each protein.
Figure 1 A cross-amyloid network between Aβ peptide and four amyloidogenic proteins. Proteins with intrinsic amyloidogenic potential are contoured by red lines. Green symbols: amyloid proteins that have a positive effect against the progression of AD. Red dashes arrow: amyloid protein pathway according to the amyloid cascade hypothesis. The details of the interactions are discussed in the review for each protein.CC BY · PubMed Central
Figure 2 Graphic representation of TTR tetramer. (A) The TTR tetramer composed by four equal monomers assembled by 222 molecular symmetry. The tetramer is crossed by thyroxin binding pockets (T4-BP). (B) The TTR tetramer rotated of 90°. (C) Representation of the dimer composed by two identical monomers. Each monomer is composed by strands D, A, G H, C, B, E and F, and a short EF α-helix.
Figure 2 Graphic representation of TTR tetramer. (A) The TTR tetramer composed by four equal monomers assembled by 222 molecular symmetry. The tetramer is crossed by thyroxin binding pockets (T4-BP). (B) The TTR tetramer rotated of 90°. (C) Representation of the dimer composed by two identical monomers. Each monomer is composed by strands D, A, G H, C, B, E and F, and a short EF α-helix.CC BY · PubMed Central
Figure 3 Schematic representation of the three different strategies employed to design anti-Aβ agents based on TTR-Aβ interactions.
Figure 3 Schematic representation of the three different strategies employed to design anti-Aβ agents based on TTR-Aβ interactions.CC BY · PubMed Central
Figure 4 Schematic representation of the design development of peptide cG8, as first TTR-derived peptide inhibitor.
Figure 4 Schematic representation of the design development of peptide cG8, as first TTR-derived peptide inhibitor.CC BY · PubMed Central
Figure 5 Graphic representation of two CysC X-ray crystal structures. (A) Cartoon of CysC-stab1 (PDB code: 3GAX) folded as a monomer. N = N-terminus, L1 = loop1, L2 = loop2, AS = irregular appending structure. The CysC-stab1 mutations L47C and G69C are colored in red. (B) Cartoon representation of CysC (PDB code: IR4C) folded as 3D domain-swapped dimer. The two molecules, which compose the dimer, are colored in yellow-orange and bright orange. L2 is conserved while L1 is transformed to form the dimer.
Figure 5 Graphic representation of two CysC X-ray crystal structures. (A) Cartoon of CysC-stab1 (PDB code: 3GAX) folded as a monomer. N = N-terminus, L1 = loop1, L2 = loop2, AS = irregular appending structure. The CysC-stab1 mutations L47C and G69C are colored in red. (B) Cartoon representation of CysC (PDB code: IR4C) folded as 3D domain-swapped dimer. The two molecules, which compose the dimer, are colored in yellow-orange and bright orange. L2 is conserved while L1 is transformed to form the dimer.CC BY · PubMed Central
Figure 6 (A) Interaction structure of the CysC-Aβ complex revealed by molecular dynamics simulation in the study of Przybylski et al. [186] (B) The binding complex from the docking output between Aβ and CysC fragment in the study of Sharma et al. [188].
Figure 6 (A) Interaction structure of the CysC-Aβ complex revealed by molecular dynamics simulation in the study of Przybylski et al. [186] (B) The binding complex from the docking output between Aβ and CysC fragment in the study of Sharma et al. [188].CC BY · PubMed Central
Figure 7 Graphic representation of Δ(185–243)apoA-I crystal structure (PDB code 3R2P). (A) Monomer of Δ(185–243)apoA-I. N-terminus 3-43 residues are colored in violet, 44-184 ligthpink. Helix repeats 1-7 are reported. (B) Homodimer representation of Δ(185–243)apoA-I. The crystallographic 2-fold axis crossed the middle of sequence repeat 5.
Figure 7 Graphic representation of Δ(185–243)apoA-I crystal structure (PDB code 3R2P). (A) Monomer of Δ(185–243)apoA-I. N-terminus 3-43 residues are colored in violet, 44-184 ligthpink. Helix repeats 1-7 are reported. (B) Homodimer representation of Δ(185–243)apoA-I. The crystallographic 2-fold axis crossed the middle of sequence repeat 5.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Items 201–254 of 254

Cited by

See all 76

Metadata

Authors
Ciccone, L., Shi, C., di Lorenzo, D., Van Baelen, A.-C., & Tonali, N.
Affiliations
  • University of Pisa (IT)
  • Centre National de la Recherche Scientifique (FR)
  • CNRS, BioCIS, Université Paris-Saclay, rue Jean-Baptiste Clément 5, 92290 Châtenay-Malabry, France
  • Département Médicaments et Technologies pour la Santé (DMTS), CEA, INRAE, Université Paris Saclay, SIMoS, 91191 Gif-sur-Yvette, France
Corresponding author
Ciccone, Lidia
Venue
Molecules
Publisher
MDPI AG
Published
2020-05-23
Volume
25
Issue
10
Pages
2439
ISSN
1420-3049 (ISSN-L)
OpenAlex
W3027358274
Cited by
69
References
256
Citations by year
2026: 5 · 2025: 16 · 2024: 6 · 2023: 11 · 2022: 11 · 2021: 15 · 2020: 5
FWCI
1.34
Type
journal article
Language
en
Open access
Locations
  • Molecules (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, cc-by)
  • HAL (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Horizon 2020 (860070)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, amyloid-beta 42, co-assembly, protein-protein interaction, tau aggregation, prealbumin, cystatin C, apolipoprotein A-I, treatment options
MeSH terms
Alzheimer Disease, Amyloid, Humans, Peptide Fragments, Prealbumin, Amyloid beta-Peptides, Apolipoprotein A-I, tau Proteins, Cystatin C, Protein Interaction Maps, Protein Aggregation, Pathological

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.